Abstract
Proteins containing advanced glycation end products are highly immunogenic and anti-advanced glycation end products antibodies (anti-AGEs antibodies) are found in the sera of diabetics. Enzyme-linked immunosorbent assay (ELISA) was used for measuring levels of anti-advanced glycation end products antibodies in sera of 93 patients with type 2 diabetes mellitus and arterial hypertension (mean age 61.4±11.3 years, diabetes duration 9.88±3.12 years; hypertension duration 9.28±4.98). These values were compared to serum anti-AGEs antibodies in 42 age and sex matched controls. Diabetics were divided in two groups according to presence or absence of microangiopathy, group 1 (n=67) and group 2 (n=26), respectively. Serum levels of anti-AGEs antibodies in patients with type 2 diabetes mellitus and arterial hypertension were statistically significantly higher than those in the control group (1.39±0.39 vs. 1.05±0.32), (p<0.05). Group 1 showed significantly higher levels of anti-AGEs antibodies than those of healthy controls (1.53±0.14 vs. 1.05±0.32), (p<0.01). Anti-AGEs antibodies levels were higher in patients with microvascular complications than these in patients without complications. Anti-AGEs antibodies correlate with diastolic blood pressure (r=0.26, p=0.05) and body mass index (r=0.37, p=0.03). We found significantly higher percentage of positive patients for anti-AGEs antibodies (mean+2SD) in group 1 than in group 2. Determining the levels of serum anti-AGEs antibodies can help physicians make early diagnosis and prognosis of the severity of late diabetic complications in hypertensive patients.
Highlights
Non-enzymatic glycation of proteins or lipids can lead to the formation of reactive advanced glycation end products (AGEs), which are thought to be implicated in the formation of micro- and macrovascular complications in diabetes.[1,2,3,4] Long living proteins such as collagen, elastin, lens crystalline and DNA are susceptible to AGE modification.[5]
Serum levels of anti-AGEs antibodies in patients with type 2 diabetes mellitus and arterial hypertension were statistically significantly higher than those in the control group (1.39±0.39 vs. 1.05±0.32), (p
Anti-AGEs antibodies levels were higher in patients with microvascular complications than these in patients without complications
Summary
Non-enzymatic glycation of proteins or lipids can lead to the formation of reactive advanced glycation end products (AGEs), which are thought to be implicated in the formation of micro- and macrovascular complications in diabetes.[1,2,3,4] Long living proteins such as collagen, elastin, lens crystalline and DNA are susceptible to AGE modification.[5] In our previous studies, we found elevated serum levels of anti-collagen type IV and anti-elastin antibodies in patients with type 2 diabetes mellitus with microangiopathy.[6,7] Reactive AGE can directly alter the physical. Proteins containing advanced glycation end products are highly immunogenic and anti-advanced glycation end products antibodies (anti-AGEs antibodies) are found in the sera of diabetics
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
